Clinical Trial Update: Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial exploring Fruquintinib combined with mFOLFOX6/FOLFIRI as first-line therapy to enable conversion surgery in metastatic colorectal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Fruquintinib (fruquintinib)
• MFOLFOX6

Snippet

Sponsor: Fudan University | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN